[Effects of phospholipid hepatoprotective agents in experimental Reye syndrome].
Saratikov
A S
AS
Vengerovskiĭ
A I
AI
Sukhodolo
I V
IV
Chuchalin
V S
VS
Arbuzov
A G
AG
Cherviakova
M B
MB
Burkova
V N
VN
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002338:Carotenoids / Q000627:therapeutic use*; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010743:Phospholipids / Q000627:therapeutic use*; D051381:Rats; D012202:Reye Syndrome / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
D000975:Antioxidants; D004338:Drug Combinations; D005229:Fatty Acids, Monounsaturated; D010713:Phosphatidylcholines; D010743:Phospholipids; C064845:eplir; C011246:essential 303 forte; D002338:Carotenoids; C009785:4-pentenoic acid